Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tissue-specific determinants of the adaptive NK cell response
    Meeting Abstract

    Mujal, A. M.; Owyong, M.; Santosa, E. K.; Wingert, C.; Grassmann, S.; Lau, C. M.; Sun, J. C. Y.
    Journal of Immunology (2023)

    Fulltext@MSK | Save
  • Design and development of IKZF2 and CK1α dual degraders
    Journal Article

    Miyamoto, D. K.; Curnutt, N. M.; Park, S. M.; Stavropoulos, A.; Kharas, M. G.; Woo, C. M.
    Journal of Medicinal Chemistry (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies
    Meeting Abstract

    Raab, M. S.; Hanel, M.; Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Raje, N.; Leleu, X.; Lesokhin, A. M.; Mohty , M.; Nooka, A.; Leip, E.; Conte, U.; Vlqueira, A.; Manier, S.
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Pooled analysis of MagnetisMM studies: Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma (RRMM) previously exposed to B-cell maturation antigen (BCMA)-directed therapies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maise, C.; Arnulf, A.; Larson, S. M.; Asya, V. Y. N.; Leleu, X.; Karlin, L.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Host interactions with engineered T-cell micropharmacies
    Journal Article

    Bourne, C. M.; Wallisch, P.; Dacek, M. M.; Gardner, T. J.; Pierre, S.; Vogt, K.; Corless, B. C.; Bah, M. A.; Romero-Pichardo, J. E.; Charles, A.; more...
    Cancer Immunology Research (2023)

    Fulltext@MSK | Save